AD Related Dementias – Specific
Develop biomarker and risk profiles to establish in-vivo diagnostic criteria for TDP-43 pathology in persons without cognitive symptoms and in persons with amnestic syndromes, e.g. amnestic MCI and AD clinical syndrome.
- Support research to develop biomarker and/or risk profiles designed to facilitate clinical trial stratification for TDP-43 proteinopathy in common dementias.
Summary of Key Accomplishments
Currently, biomarkers that reveal pathological changes in TDP-43, a protein linked to various types of dementia, are needed across all stages of disease. NIH supports multiple funding opportunities to develop biomarkers for TDP-43 neuropathology. Recently, researchers showed that detection of extremely low levels of TDP-43 may be overcome by technological advances to amplify TDP-43 from cerebral spinal fluid or isolate it from plasma. Additionally, NIH supports the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD), which is a repository for biological specimens available to researchers to help identify disease genes and support biomarker development for AD/ADRDs, including for TDP-43.
This information is current as of July 2022.
- Research Implementation Area
- AD Related Dementias - Specific
- In Progress
- RFA-NS-19-014: Center without Walls for PET Ligand Development for Alzheimer's disease related dementias (ADRDs) (U19)
Research Programs and Resources
- Center without Walls for PET Ligand Development for Alzheimer's disease related dementias (ADRDs) (U19)
- National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)